 |
 |
 |
 |
 |
Subject: Double-blind Trial of BTX-A for Drooling (Toxins 2002) Date: 6/15/2002 E-MOVE reports from the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Poster (P) and page (R) numbers are from Naunyn Schmiederberg's Archives of Pharmacology 2002;365(supplement 2).Treatment of drooling in Parkinson's disease and motorneuron disease with botulinum toxin A A Lipp, T Trottenberg, D Beyer, A Kupsch, G Arnold P79; R38 The authors conducted a randomized, placebo-controlled, double-blind trial of BTX-A in 11 patients with PD, 10 with PSP or MSA, and 11 with MND. Patients had not received anticholinergic drugs for at least 4 weeks before treatment. Patients received either placebo or 18.75 U, 37.5 U, or 75 U Dysport bilaterally to the parotid glands at baseline and again at three months. Saliva accumulation was assessed gravimetrically and drooling by subjective impression. Saliva accumulation was reduced approximately 20-40% during the first three months in a dose-dependent manner. After the second injection, patients on the two highest doses showed further reductions, while those on the lowest dose remained at approximately 20% reduction. The authors note these benefits were obtained without reported side effects, but were not always enough to affect patient satisfaction with the treatment. ---- 2002 E-MOVE conference reports are made possible in part through unrestricted educational grants from Elan Pharmaceuticals, GlaxoSmithKline, and Pharmacia Corporation. E-MOVE Editor: Richard Robinson, NASW, WE MOVE
|
|
| All contents copyright © WE MOVE 2010. This page last modified 2/25/2009. | |